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Purpose: This retrospective r view of femorodistal vein grafts was analyzed to determine 
the usefulness of various graft surveillance criteria. 
Method: The surveillance schedule involved evaluations at 1 month, every 3 months the 
first year, and then every 6 months. Salvage intervention or graft occlusion occurring 
within the next follow-up interval defined surveillance end points. One hundred two grafts 
(329 surveillance visits) had an ankle/brachial ndex (ABI). A duplex scanning-determined 
midgraft peak systolic flow velocity (PSFV) was available for 81 grafts (262 visits). 
Forty-eight grafts (137 visits) had both a PSFV and entire graft duplex scanning (EGDS) 
to determine stenosis greater than 50%, whereas 40 grafts (91 visits) had simultaneous 
ABI and EGDS. 
Results: When a greater than 15% decrease inABI denoted an abnormal surveillance study 
result, a positive predictive value (PPV) of 24.3% and negative predictive value of 94.5% 
were noted. Similarly, aPSFV cutoffofless than 35 cm/sec demonstrated values of 26.3% 
and 94.2%, respectively. When an EGDS of greater than 50% stenosis or a PSFV of less 
than 35 cm/sec were the cutoff criteria, the PPV was 36.7% and negative predictive value 
99.1%, whereas characterizing abnormal results further with ABI (> 15% $ ) increased 
the PPV to 83.3%. 
Conclusion: The combination of an EGDS, midgraft PSFV, and ABI provides optimal 
follow-up for our patients with a femorodistal vein graft. (J VAsc SURG 1995;21:127-34.) 
Graft surveillance has been reported to improve 
overall graft patency and limb salvage by defining 
grafts in jeopardy of failure, thereby allowing in- 
tervention before graft occlusion. 17 Several methods 
of graft surveillance have been advocated over the 
years, often changing with the advent of new 
technology. 1-17 The most commonly used and least 
invasive methods have involved ameasurement of the 
ankle/brachial systolic blood pressure index (ABI) or 
duplex scanning of the graft. This retrospective study 
of graft surveillance by use of these two modalities 
was undertaken to determine which surveillance 
criteria would be most useful in monitoring our series 
of femorodistal vein bypass grafts. 
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METHODS 
This study involves patients who required a 
femorodistal vein graft for limb salvage surgically 
treated from 1985 to 1991 at atertiary care facility or 
a primary care city hospital, with follow-up extending 
to 1993. Choosing this group of patients guaranteed 
that all studies were performed by the same certified 
vascular laboratory personnel under the supervision 
and interpretation provided by the same vascular 
surgeons. Some method of graft surveillance has been 
an integral component of follow-up in patients with 
distal bypass grafts throughout this period of time. 
Initially, an ABI determination was the sole surveil- 
lance study. Beginning in late 1986, a duplex 
determination of the midgraft peak systolic flow 
velocity (PSFV) was added. A more extensive and 
complete imaging of the graft with the duplex 
instrument was begun in 1988. 
The ABI recorded for this study was the ratio of 
the highest recorded ankle pressure to the highest of 
the two simultaneously measttred brachial artery 
systolic pressures. 
The duplex scanner used to obtain an image of the 
graft changed uring the course of the study from an 
ATL Ultramark 4 to an Ultramark 9 (Advanced 
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Fig. 1. This is graphic representation f number of grafts 
experiencing surveillance end points (occlusion or need for 
salvage intervention) during each scheduled surveillance 
time interval. Number of graft occlusions is depicted by 
double hash marks. Number at top of each bar denotes 
number of grafts available for surveillance at each time 
interval. 
Technology Laboratories, Bothell, Wash.). Initially, 
a single midgraft PSFV was obtained approximately 
8 cm below the knee for those grafts with a distal 
anastomosis below midcalf or 8 cm above the knee 
for those with a more proximal anastomosis. The 
PSFV was measured midstream at an angle 60 
degrees to the long axis of the graft. This allowed 
measurement a a standard location and in an area of 
the bypass not subject o abrupt diameter changes or 
changes in vessel direction. Because of some initial 
dissatisfaction with this single value determination 
and some question of its usefulness in the literature, 12 
an entire graft duplex scanning study (EGDS) was 
performed measuring the velocity of blood flow at 
peak systole continuously along the entire graft and 
anastomotic areas. If narrowing was found, it was 
classified as a diameter eduction of less than 50% or 
greater than 50%. Alternatively, a graft occlusion 
could be documented. A duplex scanning-deter- 
mined velocity ratio (maximal PSFV within the 
stenosis/the PSFV in the normal graft above the 
stenosis) of 2 or greater indicated a diameter stenosis 
of greater than 50%. 1°,13,18 
The results of all surveillance studies were re- 
ported to the referring surgeon with interpretation, 
and further management was determined solely by 
Table I. The surveillance nd points are 
stratified by type of conduit and by the 
location of the vascular defect with respect 
to the graft 
Graft conduit 
Location of In situ Reverse Arm vein 
vascular defect (n = 74) (n = 20) (n = 2) 
Inflow 1 
Graft/anastomotic 11 5 1 
Outflow 2 
Thrombosis 9 6 1 
Total 23 11 2 
that physician and was noted for the purpose of this 
study by retrospective chart review. 
Because this study was concerned with the utility 
of graft surveillance criteria to define grafts in 
jeopardy of impending failure, only grafts with at 
least two surveillance visits were included. Our 
routine surveillance protocol called for laboratory 
studies to be performed 1 month after reconstruc- 
tion, every 3 months for the first year, and every 6 
months thereafter. I f  more frequent tests were 
obtained, these results were ignored for the purpose 
of this investigation. Graft occlusion or intervention 
performed to prevent graft failure before the next 
scheduled follow-up visit constituted a surveillance 
end point. I f  a graft was salvaged, it was monitored 
in exactly the same way as a new graft in that a 
surveillance study was obtained at 1 month, every 3 
months for 1 year, and then every 6 months. 
Graft surveillance protocols were successfully 
monitored as required for this study in 112 femoro- 
distal vein grafts (96 initial and 16 salvaged grafts) for 
419 surveillance visits. Individual graft surveillance 
methods were used to monitor grafts for an average 
of 17.6 months (range 16.9 to 18.3) with a standard 
deviation of 15.6 months (range 14.9 to 16.3), with 
some overlap obviously present. The conduit was 
positioned in situ in 74 and reversed in 20 and was 
an arm vein in two cases. The distal anastomosis was 
performed to the anterior final artery in 31 cases, 
posterior tibial in 39, and peroneal in 26. The graft 
originated from the common femoral artery in 88 
cases and the popliteal in eight. There were 36 
surveillance nd points met and were temporally 
distributed as shown in Fig. 1. The breakdown of 
surveillance end points by conduit type and by 
location with respect to the bypass graft when known 
is provided in Table I. 
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Accuracy statistics were determined for select 
cutoff values for each individual combination of 
surveillance methods used. A given test criteria 
defined a true-positive r sult if the test suggested a 
graft in jeopardy and the graft failed or required an 
intervention to correct a significant anatomic defect 
before the next scheduled surveillance visit. Con- 
versely, a true-negative r sult was a given criteria 
suggesting no graft problem and the graft remained 
patent without he need for any salvage intervention. 
A false-negative study result meant that the graft 
failed or required salvage intervention when the 
surveillance study suggested no problem, whereas a
false-positive t st result meant that he graft remained 
patent when the test criteria suggested a failing graft. 
The sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and overall 
accuracy were calculated from the data generated. 19 
Statistical analysis used to compare the different 
surveillance tests and their various cut-off criteria 
arranged the true-positive and false-negative alues 
obtained for each into contingency tables. First, the 
data were analyzed by chi-squared analysis to deter- 
mine whether any differences existed between and 
within any of the methods used and their select cutoff 
criteria. The Fisher exact est was used for individual 
comparisons. All analyses were performed with the 
Sigma Stat Software for Windows 1.0 (Jandel 
Scientific Software, San Rafael, Calif.). Significance 
required a p value less than 0.05. Furthermore, it 
should be remembered that in a population with a 
low disease prevalence, asis true in this population, 1-7 
a desirable screening test should have a high NPV and 
low false-negative rate to optimize the chance of 
defining those at risk. 19 
RESULTS 
ABI. One hundred two grafts in 80 patients were 
monitored with ABIs as a surveillance tool for 329 
surveillance visits. Thirty-two surveillance end points 
were noted. Three different ABI surveillance criteria 
were used to define grafts in jeopardy: agreater than 
10%, greater than 15%, or greater than 20% decrease 
in the ABI between surveillance visits. Table II 
contains the conditional probabilities calculated from 
the data gathered. The false-negative end points for 
the greater than 10% cutoff level presented as eight 
graft occlusions (one reopened with urokinase, but 
no obvious cause for thrombosis was found, and one 
thrombectomy, which defined a distal native vessel 
stenosis requiring a vein patch angioplasty), two 
grafts requiring a percutaneous transluminal ngio- 
plasty, and two grafts requiring avein patch angio- 
Table II. The criteria for change in ABI 
between surveillance visits, which would 
indicate a graft in jeopardy of failure along 
with the accuracy parameters calculated for 
each set of criteria 
% Decrease in AB I  
Accuracy 
parameter > 10% > 15% > 20% 
Sensitivity 62.5% 56.2% 53.1% 
Specificity 71.7% 81.1% 87.9% 
PPV 19.2% 24.3% 32.1% 
NPV 94.7% 94.5% 94.5% 
Overall accuracy 70.8% 78.7% 84.5% 
False-negative 12 14 15 
False-positive 84 56 36 
The actual number of false-negative and false-positive t st results 
is provided. 
plasty to eliminate a greater than 50% stenosis. Three 
graft occlusions represent he additional false- 
negative results noted at the 15% and 20% cutoff 
levels. 
Duplex study: Midgraft PSFV. Midgraft du- 
plex scanning-determined PSFV was obtained in 81 
infrapopllteal bypass grafts (63 patients) as part of the 
surveillance protocol. There were 262 surveillance 
visits and 19 surveillance nd points were docu- 
mented. Three cutoff values were chosen for accuracy 
calculations: a less than 45 cm/sec, less than 35 
cm/sec, or less than 25 cm/sec PSFV as recorded in 
the midgraft location. Table III provides the prob- 
abilities calculated for each defined criteria. The 
underlying problems resulting in surveillance nd 
points and translating into false-negative r sults for 
the less than 45 cm/sec level were two graft throm- 
boses (cause unknown), 10 stenoses (> 50%), of 
which four required a distal anastomotic vein patch 
angioplasty, three a graft PTA, two a graft vein patch 
angioplasty, and one a valve cusp lysis in addition to 
one case requiring ligation of an arteriovenous fi tula 
for graft salvage. At the less than 35 cm/sec utoff 
level, an additional midgraft vein patch angioplasty 
for stenosis greater than 50% was required before the 
next scheduled surveillance visit. At the less than 25 
cm/sec level, two additional graft thromboses and 
one graft PTA, one graft vein patch angioplasty, and 
one distal anastomotic vein patch angioplasty were 
required for significant stenoses, and each was 
unsuspected bythis surveillance criteria. 
Both an ABI and mid-graft PSFV were available 
in 65 grafts in 55 patients. Thirteen surveillance end 
points were documented during 172 surveillance 
intervals. A positive study result was defined as 
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Table III. Midgraft PSFV criteria and 
accuracy parameters calculated for each 
separate criteria 
Midgraft peak systolic flow velocity 
Accuracy 
parameter < 45cm/sec < 35 cm/sec < 25 cm/sec 
Sensitivity 31.6% 26.3% 0% 
Specificity 81.1% 94.2% 99.2% 
PPV 11.5% 26.3% 0% 
NPV 93.8% 94.2% 92.7% 
Overall accuracy 77.5% 89.3% 92% 
False-negative 13 14 19 
False-positive 46 14 2 
The number of false-negative and false-positive test results is 
included. 
having one or both of the following: a PSFV of less 
than 35 cm/sec, a greater than 15% decrease in the 
ABI. The sensitivity calculated was 69.2%, specificity 
73.0%, PPV 17.3%, NPV 96.7%, and the overall 
accuracy was 72.7%. The false-negative r sults were 
four in number, and the false-positive r sults were 43. 
EGDS to determine diameter stenosis of 
greater than 50%. A duplex scanning determination 
of stenoses in or directly adjacent to the graft in 
addition to a midgraft PSFV was obtained in 48 vein 
grafts (38 patients) during 137 surveillance visits. 
Twelve surveillance nd points were observed. If a 
diameter reduction of greater than 50% was defined 
as the criteria that would separate a positive from a 
negative surveillance xamination result, the condi- 
tional probabilities calculated are shown in Table IV. 
The three false-negative r sults failed to suggest an 
impending raft thrombosis (cause unknown), the 
need for a graft PTA, and the need for a distal jump 
graft within the subsequent surveillance interval. If 
the criteria for an abnormal test result was modified 
to require a greater than 50% diameter stenosis by 
EDGS or a less than 35 cm/sec PSFV, the accuracy 
statistics calculated are also given in Table IV. The 
one false-negative r sult failed to predict he subse- 
quent need for a graft PTA within the next surveil- 
lance interval. If one then considers the presence or 
absence of an ABI reduction of greater than 15 % only 
in the latter duplex surveillance study results which 
were abnormal, anew set of conditional probabilities 
can be tabulated (n = 22): the sensitivity is 71.4%, 
specificity 93.3%, PPV 83.3%, NPV 87.5%, and 
overall accuracy 86.4%. There were two false- 
negative results and one false-positive r sult in this 
very select group. 
An EGDS in addition to a simultaneous ABI was 
obtained in 40 grafts with 91 surveillance visits. Eight 
Table IV. The accuracy parameters 
calculated when a > 50% DR is identified 
by duplex imaging of the vein graft or when 
the surveillance study result was considered 
positive if either one or both of the 
following existed: a > 50% DR, a midgraft 
PSFV of < 35 cm/sec 
Either one or both 
Accuracy > 50% DR 
parameter > 50% DR PSFV <35 cm/sec 
Sensitivity 75% 91.7% 
Specificity 92% 84.8% 
PPV 47.4% 36.7% 
NPV 97.5% 99.1% 
Overall accuracy 90.5% 85.4% 
False-negative 3 1 
False-positive 10 19 
DR, Diameter reduction. 
The number of false-negative and false-positive test results are 
included. 
surveillance nd points were met. Defining the 
presence of an ABI decrease of greater than 15% or 
a EGDS documented greater than 50% stenosis as a 
positive study result, the sensitivity calculated was 
87.5%, specificity was 72.3%, PPV was 23.3%, NPV 
was 98.4%, and overall accuracy was 73.6%. 
Statistical comparisons. Fig. 2 expresses each 
surveillance method and respective cutoff criteria by 
receiver operating characteristic urves. All nine 
combinations were studied collectively by chi- 
squared analysis and significant differences were 
suggested by ap value less than 0.05. No significant 
differences were found between any ABI cutoff 
criteria: greater than 10%, greater than 15%, greater 
than 20% $ nor when a PSVF less than 35 cm/sec 
was considered in addition. Results obtained by use 
ofa cutoff criteria of less than 35 cm/sec or less than 
45 cm/sec for a midgraft PSFV were not statistically 
different, but those observed at the less than 25 
cm/sec level were less predictive (2 < 0.05). Com- 
paring our clinically used ABI cutofflevel ( > 15 $ ) 
to the PSFV with the numerically best NPV dem- 
onstrated a significant difference in predictive value 
(Fisher exact est, p = 0.047). The results obtained 
whenever an EGDS determination of diameter ste- 
nosis (>50%) was available, either alone or in 
combination with an ABI (> 15% $) or PSFV 
( < 35 cm/sec), resulted in statistically similar predic- 
tive values. The EGDS study with the best numerical 
NPV (a combination of an EGDS determination of
greater than 50% stenosis and PSFV less than 35 
cm/sec as the cutoff criteria) demonstrated statisti- 
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cally different results from those obtained with the 
ABI surveillance study (> 15% $ cut-off criteria, p
value = 0.035), or the PSVF study (< 35 cm/sec 
cut-off criteria, p = 0.0006) alone. 
DISCUSSION 
This study confirms that most femorodistal vein 
bypass grafts fail within the first postoperative y ar, 
thereby stressing the need for frequent surveillance 
during this time. This fact holds true whether the 
conduit is in situ. 1'3'7'12 reversed 1'3'~s'16 or from an 
arm vein. 17 
A simple ABI would be an ideal surveillance study 
because it can rapidly be performed by any trained 
observer, is known to be an improvement over 
clinical indicators alone, and requires only a rather 
inexpensive Doppler scanning unit for comple- 
tion. ~4,1s The problem with this surveillance tool, in 
our experience, is a lack of predictive value. A NPV 
of slightly less than 95% may appear acceptable tothe 
casual observer because it represents only 12 to 15 
false-negative study results from a series of 329 
surveillance visits. However, it must be remembered 
that graft patency is of primary concern, and this 
NPV translates into 12 to 15 unsuspected grafts in 
jeopardy out of 102 total grafts at risk (90 initial plus 
I2 salvaged grafts). In other words, up to i5% of our 
grafts could fail during a surveillance interval on the 
basis of simple ABI determinations. Furthermore, no 
matter what level of ABI criteria is used as the 
surveillance cutoff, a positive study result will really 
represent a graft in jeopardy less than one third of the 
time. This would translate into 36 to 84 unnecessary 
angiograms if one strictly studied all patients with a 
positive test result. Many investigators have found 
similar findings when using alterations in ABI 
readings as the sole graft surveillance tool. 2,s-8,1°,2° 
Barnes et al. 2° drew attention to the problem when he 
found that an ABI decrease of greater than 0.20 could 
not reliably predict graft failure, nor could the lack of 
such a change nsure continued graft patency. Even 
when investigators clearly documented a greater than 
50% diameter stenosis in a graft, an ABI decrease of 
greater than 15% was confirmatory in only 13% to 
38% of cases. 7,1° 
The addition of a duplex scanning-determined 
midgraft PSFV to our distal vein graft surveillance 
protocol was stimulated by the findings of Bandyk et 
al.2 They determined the PSFV slightly above the 
distal anastomosis to best maintain a constant vessel 
diameter and easy access for duplex evaluation. The 
current study determined the PSFV a short distance 
above or below the knee for the same reasons and 
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Fig. 2. This graft depicts receiver operating characteristics 
curves for surveillance modalities under study. ABI sur- 
veillance study at various cutoff criteria re shown as circles 
(A is >20%, B is >15%, C is >10% decrease in ABI 
values between surveillance visits). Combination of ABI 
> 15% $ or PSFV < 35 cm/sec as cutoff criteria is marked 
with asterisk. PSFV surveillance r sults at various cutoff 
levels are shown as squares (E is < 25 cm/sec, F is < 35 
cm/sec, G is < 45 cm/sec as cutoff criteria). Studies with 
component being EGDS determination of stenosis 
(> 50%) are marked by triangles (H is EGDS (> 50% 
stenosis) alone, Iis EGDS ( > 50% stenosis) or PSFV < 35 
cm/sec,Jis EGDS ( > 50% stenosis) and/or ABI > 15% $ 
as criteria to determine abnormal study result). 
because the distal graft was sometimes routed deeply, 
making standardization f a routine distal location 
otherwise difficult. A single duplex scanning-deter- 
mined midgraft PSFV achieved a NPV similar to 
that seen with changes in ABI. Of 81 graft surveil- 
lance protocols begun, 13 to 19 grafts would not 
have been identified at risk even though a surveillance 
end point was reached. Therefore 16% to 23.5% of 
grafts might fail when a single midgraft PSFV was 
used as the surveillance study of choice. Similarly, the 
PPV was less than 30%, which would translate into 
a significant number of negative confirmatory angio- 
grams. With a PSFV of less than 45 cm/sec as the 
criteria to define a graft in jeopardy of failure, a PPV 
of 15% to 31% has been reported in the literature. 6'~3 
It does not appear that a given low PSFV per se 
denotes a graft in jeopardy. This finding has been 
observed in several clinical series 6'9'11,21'22 and even 
more elegantly in a prospective manner by Belkin et 
al.23 Belkin et al.22,23 has shown that the PSFV is 
determined by the local vein graft diameter and by the 
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outflow resistance, the latter being a difficult mea- 
surement o determine precisely in a noninvasive 
manner. One must either control for these variables 
(i.e:, a diameter specific range of acceptable PSFV 
values or measure outflow resistance) or have an 
"internal control" that clinically has translated into 
the use of a PSFV ratio to compare the stenotic to a 
normal area. 
Performance of an EGDS of distal vein grafts in 
a search for significant areas of diameter reduction 
(> 50% stenosis) has proven to be our best overall 
surveillance tool with an accuracy of 90.5%. Statis- 
tically an EGDS study is more predictive than any 
ABI or PSFV surveillance study evaluated. This 
finding is not surprising because most problems 
placing grafts in jeopardy in our study (85% of those 
cases with a known cause) occurred in the conduit or 
perianastomotic areas, which is the precise location 
under most intense scrutiny with this surveillance 
modality. The propensity for problems to occur in 
these locations is seen with in situ, reverse, or arm 
vein bypasses at a rate of 59.6% to more than 90% of 
cases .  1'a'6'16'I7 A NPV of 97.5% translates into only 
three false-negative r sults during 137 surveillance 
visits of 48 grafts. One patient was admitted with 
symptoms during the intervening surveillance inter- 
val and required agraft PTA, one graft occluded, and 
one patient underwent angiography for a low mid- 
graft PSFV and a decrease in the ABI, which 
demonstrated a istal native artery occlusion requir- 
ing a vein jump graft o the dorsalis pedis. A PPV of 
47.4% compares favorably with a 32% PPV reported 
by Mattos et al.6 Of the 10 false-positive study results, 
two sequential studies, both from the same graft, 
demonstrated regression from a greater than 50% 
diameter eduction to a less than 50% stenosis at 
about 1 year of follow-up and remained so for 27 
months, at which time PTA of a graft stenosis was 
required. All other grafts in which a greater than 50% 
diameter reduction was noted and that were moni- 
tored with an EGDS demonstrated persistence or 
progression of the area of stenosis. Certainly, the 
PPV would have been dramatically improved if the 
definition of grafts in jeopardy had spanned a longer 
time interval, but, as defined in this study, some grafts 
with a greater than 50% stenosis urvived the 3- or 
6-month interval between surveillance visits without 
occlusion or intervention. The observation that a 
greater than 50% diameter reduction is not a benign 
process has been confirmed by other investiga- 
tors. 6'7'9 One group has reported a 46% 1-year 
occlusion rate when a diameter stenosis of greater 
than 50% was noted and merely followed. 6 Our 
tendency is to proceed with angiography and inter- 
vention when faced with such lesions rather than to 
hope for a benign natural history. 
Combining graft surveillance visits in which 
both an ABI and PSFV were obtained improved 
the NPV but not overall accuracy because the PPV 
was only 17.3%. The ABI cutoff level (a greater 
than 15% decrease between surveillance visits) was 
chosen for this comparison because it is routinely 
used clinically in our institution and was not found 
to be statistically different from any other ABI 
cutoff criteria evaluated. The PSFV level of less than 
35 cm/sec was chosen because it provided the best 
numeric NPV and PPV when compared to the less 
than 45 cm/sec level, even though statistically the 
results were similar at the sample size available. Four 
false-negative r sults were observed: two graft oc- 
clusions and two graft stenoses uggested by a 
duplex scanning-determined narrowing ( > 50%), 
both of which required a patch angioplasty. One 
might argue that the last two grafts had not reached 
a critical degree of flow reduction sufficient to 
decrease the midgraft PSFV nor the ABI and 
therefore were not truly grafts in jeopardy. Such an 
argument ignores the fact that a significant lesion 
was confirmed by angiography, the current, albeit 
debatable, gold standard, and that such lesions tend 
to have less than a benign course .  6'7'9 It might better 
be agreed that two studies that appear to measure 
overall imb perfusion (ABI) or graft function as a 
component of overall limb perfusion (midgraft 
PSFV) when combined do not off set the defi- 
ciencies inherent in each. 
The addition of a midgraft PSFV ( < 35 cm/sec) 
to an EGDS resulted in an NPV of 99.1%, missing 
only one surveillance nd point. Although not 
statistically different from the results obtained when 
the EGDS study alone was used, this combination 
did provide a numerically superior NPV, which is 
desirable for a surveillance study investigating a
population with a low prevalencc disorder. The 
thought was to add a study that attempts to evaluate 
overall limb perfusion to the very accurate graft 
specific EGDS evaluation of localized stenosis. The 
PPV, however, did suffer somewhat, decreasing from 
47.4% to 36.7% when compared with the situation 
where diameter reduction alone was used as the sole 
surveillance criteria. Mattos et al.6 found a similar 
PPV (21%) when combining these two methods of 
graft surveillance, the PSFV used in that study was 
less than 45 cm/sec. Of  the 30 test results believed to 
be positive in our study, 22 had a simultaneous ABI 
obtained. Defining a greater than 15% decrease inthe 
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ABI between surveillance visits as being significant in 
this select population, the PPV was increased to 
83.3%, but two false-negative results clouded this 
improvement.  Based on what we have concluded 
regarding grafts with a greater than 50% diameter 
reduction, angiography would preferentially be per- 
formed in such cases. This would leave nine cases 
with only a low PSFV to define a positive test result. 
Because all significant graft stenoses are defined by 
an EGDS,  the remaining cases of  low PSFV must 
reflect problems with outf low resistance, 22,23 outf low 
obstruction, 1° or possibly even inflow disease. 16 I f  
one uses an ABI  decrease of  greater than 15% to 
define a graft in true jeopardy in those with only 
a low midgraft PSFV (< 35 cm/sec) to suggest a 
problem, eight grafts would have been correctly 
categorized as free of  disease, whereas the remaining 
one would have been correctly diagnosed as having 
a distal tibial artery occlusion confirmed by angi- 
ography. This approach, o f  course, would be in- 
appropriate for inframalleolar grafts because the cuff 
placement could not allow evaluafon of  arteries 
distal to the graft. A duplex study of  these superficial 
vessels could easily take the place of  an ABI study 
in these few cases, none of  which occurred in our 
study. 
In conclusion, our current experience suggests 
that an EGDS,  in addition to a midgraft PSFV, all 
o f  which is normal  (no area of  diameter eduction 
greater than 50% and with a midgraft PSFV of  
>_2 35 cm/sec) defines grafts with a negligible chance 
of  failure when viewed within the confines of  this 
study's surveillance intervals. Documented areas of  
stenosis greater than 50% should be considered for 
further study or intervention. Grafts with simply a 
low PSFV (<35 cm/sec) to suggest impending 
graft failure should be further investigated by an 
ABI. I f  a greater than 15% decrease in sequential 
ABI  determinations i observed, then angiography 
should document  whether a stenosis external to the 
graft itself is o f  concern. What  this means in 
practical terms is that a reference ABI is required 
to observe a change at a later date. Therefore our 
current best surveillance protocol includes an EGDS 
with a midgraft PSFV determination in addition to 
a simple ABI at each surveillance visit. These data 
present the findings of  one group of  investigators, 
other investigators have found slightly different 
parameters to be useful in monitor ing their 
patients? ,s8,17 Delineation of  the optimal surveil- 
lance method for monitor ing femorodistal vein 
grafts may ultimately require a prospective, ran- 
domized evaluation. 24 
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